Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of disulfiram plus nivolumab for gastric cancer
jRCTs031180183Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of disulfiram and nivolumab in gastric cancer (GC) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Rate of dose-limiting toxicities. Started Apr 2019; status: completed.
02
Drugs
disulfiramnivolumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs031180183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180183.